Dana–Farber Cancer Institute

Children welfare groups receive donation from PCI Powerhouse Fund

Retrieved on: 
Friday, December 22, 2023
Other Retail, Philanthropy, Specialty, Other Transport, Publishing, Foundation, Retail, Marketing, Advertising, Communications, Transport, Other Philanthropy, Logistics, Supply Chain Management, Home, Corporate social responsibility, Entrepreneurship, Culture, Partnership, PCI, Multimedia, CFO, Hope, Dana–Farber Cancer Institute, Education, Black, Heart, OneHope, Creative, Love, Closet, Growth, Human resources, Organization, Engagement, Social responsibility, Senior, Management

In keeping with its commitment to give back to the community, industry leader Postal Center International (PCI) contributed from its PCI Powerhouse Fund to three deserving South Florida-based organizations dedicated to children and youth welfare on Wednesday, December 6, 2023.

Key Points: 
  • In keeping with its commitment to give back to the community, industry leader Postal Center International (PCI) contributed from its PCI Powerhouse Fund to three deserving South Florida-based organizations dedicated to children and youth welfare on Wednesday, December 6, 2023.
  • The check was part of a donation from the PCI Powerhouse Fund to several South Florida-based children's welfare organizations.
  • “Taylor's Closet is honored to receive support from the PCI Powerhouse Fund.
  • Established in December 2022, The PCI Powerhouse Fund is focused on youth wellness and education.

EMBR LABS ANNOUNCES PUBLICATION OF GROUNDBREAKING STUDY ON HOT FLASHES IN PROSTATE CANCER PATIENTS IN PRESTIGIOUS NATURE JOURNAL

Retrieved on: 
Thursday, December 21, 2023
Quality of life, Prostate cancer, Prostate, Research, Dana–Farber Cancer Institute, Disease, Prostate Cancer Foundation, MD, Hot, Estate (law), Temperature, Death

BOSTON, Dec. 21, 2023 /PRNewswire/ -- Embr Labs, Inc , makers of Embr Wave®, the leading temperature wearable, today announced the publication of "Feasibility of a Novel Wearable Thermal Device for Management of Bothersome Hot Flashes in Patients with Prostate Cancer" in Nature Journal's Prostate Cancer and Prostatic Diseases.

Key Points: 
  • BOSTON, Dec. 21, 2023 /PRNewswire/ -- Embr Labs, Inc , makers of Embr Wave®, the leading temperature wearable, today announced the publication of "Feasibility of a Novel Wearable Thermal Device for Management of Bothersome Hot Flashes in Patients with Prostate Cancer" in Nature Journal's Prostate Cancer and Prostatic Diseases.
  • A first of its kind study, Embr labs collaborated with the Dana-Farber Cancer Institute in groundbreaking research in which men with prostate cancer found the Embr Wave device effective at managing hot flashes brought on by cancer treatment.
  • This is the first study to evaluate the feasibility of a wearable thermal device for nonmedicinal management of impactful hot flashes in prostate cancer patients.
  • "This study, using a novel technology to manage hot flashes, truly moves the field forward in improving the quality of life for men with prostate cancer."

Burjeel Holdings Oncology Conference Marks 10 Years, Focusing on Equitable Solutions for Cancer Care

Retrieved on: 
Tuesday, December 19, 2023
Conference, National Cancer Institute, Alternative, Partnership, World Bank, Research, Chairperson, Dana–Farber Cancer Institute, White, Cancer Moonshot, Brigham and Women's Hospital, Congress, Society, Cancer, Health equity, AI, Nutrition, Future, Assistant, Face, Child, Patient, Bristol Myers Squibb, Foreign Policy, Policy, World Bank Group

WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- The 10th anniversary of the Burjeel Holdings Oncology Conference, held in partnership with Foreign Policy, brought together leading global experts to tackle the complex challenges of cancer care, emphasizing the need for multi-stakeholder collaboration. With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, the conference underscored the urgency of international action and equity in access to life-saving treatments.

Key Points: 
  • With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, the conference underscored the urgency of international action and equity in access to life-saving treatments.
  • Hannah Adams, a pediatric cancer survivor, reminded the audience that "the most effective advocates put a face and a name to the child of cancer."
  • The Future of Cancer Care panel delved into the potential of AI, equity considerations, and global access.
  • The Burjeel Holdings Oncology Conference served as a powerful call to action, urging individuals to support research, advocate for patient-centered policies, and raise awareness.

Burjeel Holdings Oncology Conference Marks 10 Years, Focusing on Equitable Solutions for Cancer Care

Retrieved on: 
Tuesday, December 19, 2023
Conference, National Cancer Institute, Alternative, Partnership, World Bank, Research, Chairperson, Dana–Farber Cancer Institute, White, Cancer Moonshot, Brigham and Women's Hospital, Congress, Society, Cancer, Health equity, AI, Nutrition, Future, Assistant, Face, Child, Patient, Bristol Myers Squibb, Foreign Policy, Policy, World Bank Group

WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- The 10th anniversary of the Burjeel Holdings Oncology Conference, held in partnership with Foreign Policy, brought together leading global experts to tackle the complex challenges of cancer care, emphasizing the need for multi-stakeholder collaboration. With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, the conference underscored the urgency of international action and equity in access to life-saving treatments.

Key Points: 
  • With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, the conference underscored the urgency of international action and equity in access to life-saving treatments.
  • Hannah Adams, a pediatric cancer survivor, reminded the audience that "the most effective advocates put a face and a name to the child of cancer."
  • The Future of Cancer Care panel delved into the potential of AI, equity considerations, and global access.
  • The Burjeel Holdings Oncology Conference served as a powerful call to action, urging individuals to support research, advocate for patient-centered policies, and raise awareness.

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
Sunday, November 19, 2023
Temozolomide, Safety, Glioblastoma, Dana–Farber Cancer Institute, GBM, Molecular medicine, Medicine, TMZ, Patient, Tokyo Stock Exchange, Immunohistochemistry, Neoplasm, Integrin alpha M, Harvard Medical School, Survival, CD74, Cleveland Clinic, Society, SNO, CD3, Standard Market Design, Life, Biopsy, Code, Pharmaceutical industry, Neurology

The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.

Key Points: 
  • The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.
  • MN-166 (ibudilast) and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported.
  • We are eager to evaluate MN-166 (ibudilast) in combination with anti-PD1 and anti-PD-L1 therapies in a future clinical trial.
  • MediciNova is grateful to the patients and families for their invaluable participation in our trial.”

CoRegen Appoints Edward J. Benz, M.D., to its Board of Directors

Retrieved on: 
Thursday, November 16, 2023
Research, Johns Hopkins, Yale University, Hope, Dana–Farber Cancer Institute, Disinformation Governance Board, Patient, Princeton University, Friends, Harvard Medical School, Cancer, Johns Hopkins Hospital, American Society of Hematology, Society, Nursing Research, Sir, Pharmaceutical industry, Medicine, Boston

HOUSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, announced today the appointment of Edward J. Benz, M.D., to its Board of Directors.

Key Points: 
  • HOUSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, announced today the appointment of Edward J. Benz, M.D., to its Board of Directors.
  • “We are honored to welcome Dr. Benz to CoRegen's Board of Directors, a distinguished leader whose legacy at Dana-Farber Cancer Institute and profound impact on cancer research speak volumes,” said Steve Gorlin, executive chairman and chief executive officer of CoRegen.
  • "We are entering a transformative era in cancer research, and the addition of Dr. Benz to CoRegen's Board of Directors could not have come at a more opportune time.
  • Dr. Benz will be an invaluable asset as we plan to enter the clinic, building on the legacy he has established in cancer care.

Proxygen Announces Formation of Scientific Advisory Board

Retrieved on: 
Wednesday, November 15, 2023
MSD, DRS, Broad Institute, DNA, Limited partnership, National academy, Dana–Farber Cancer Institute, Patient, Research, Ubiquitin, Pharmacology, Therapy, Chromatin, Pioneer, Drug discovery, Cancer, Diabetes, Harvard University, Field, Howard Hughes Medical Institute, Translation, Organization, MIT, European, Jude the Apostle, Merck & Co., Austrian Academy of Sciences, Max Planck Society, Translational medicine, Leibniz Prize, JDRF, Pancreatic cancer, Ernst Jung Prize, Biochemistry, SAB, EMBO, Publishing, Louis-Jeantet Prize for Medicine, Pharmacia, Glioblastoma, Boehringer Ingelheim, Medicine, Biotechnology, Genomics, Doctor of Philosophy, Monroe Dunaway Anderson, Biology, DNA repair, Pharmaceutical industry, Science, Merck

VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB). The newly appointed SAB, which is comprised of highly regarded thought leaders in the emerging field of protein degradation, will offer scientific expertise and guidance to Proxygen as the company works to advance its internal molecular glue degrader programs toward clinical development. In addition to its internal programs, Proxygen is also actively engaged in strategic research collaboration and license agreements with Merck & Co (known as MSD outside the U.S. and Canada), Boehringer Ingelheim and Merck KGaA designed to jointly identify and develop novel molecular glue degraders.

Key Points: 
  • SAB Comprised of Pioneers in the Field of Protein Degradation, Including Unique Expertise in Roles of Ubiquitin Biology and Translational Medicine
    VIENNA, Austria, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s scientific advisory board (SAB).
  • Schulman and Draetta to the Proxygen team as key advisors and pair them with Drs.
  • Winter and Kubicek, who co-founded the company, based on their trailblazing research at CeMM,” said Bernd Boidol, Ph.D., chief executive officer of Proxygen.
  • By streamlining and fully integrating cutting-edge genomic, proteomic, and biochemical technologies, Proxygen has successfully developed a highly versatile glue degrader discovery engine.

Aspira Women’s Health Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Transfer, Assistant, Woman, Methodist Hospital, Research, Senior, Gynecologic Oncology (journal), Travel, University, Conference call, Risk, Gynaecology, Protein, MicroRNA, Dana–Farber Cancer Institute, Algorithm, Medical Affairs Bureau, Marketing, Metadata, AUP, COVID-19, Conference, Ovarian cancer, Harvard Medical School, University of Oxford, Brigham, CAB, Reproductive biology, Medical school, Aspira, Government, AACR, Hospital, Video game, Arms industry, Rare-earth element, Pharmaceutical industry, Birth control, Cryptocurrency, Obstetrics

AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the three- and nine-month period ended September 30, 2023.

Key Points: 
  • “We are pleased to report another quarter of year-over-year growth, with revenues this quarter of $2.2 million.
  • The Company expects general and administrative expenses to remain flat for the fourth quarter of 2023.
  • Our cash balance this quarter benefited from the registered direct offering where we raised $4.7 million in gross proceeds.
  • The Company reiterates its operating cash utilization target for the second half of 2023 to between $6.0 million and $8.0 million.

Enterome to Present Updated Data From Phase 1/2 ROSALIE Trial of its Peptide-Based Immunotherapy EO2401 in Recurrent Glioblastoma at SNO 2023

Retrieved on: 
Monday, November 13, 2023
Dana–Farber Cancer Institute, Bevacizumab, Glioblastoma, Patient, Inflammation, Pakistan Society of Neuro-Oncology, Neuro-Oncology (journal), Harvard Medical School, Nivolumab, Immunotherapy, Society, SNO, Official Journal, Pharmaceutical industry, Medicine

PARIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced it will present updated efficacy data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in patients with first progression/recurrence of glioblastoma (the EOGBM1-18/ROSALIE study), in an oral presentation at the Society for Neuro-Oncology (SNO) 28th Annual Meeting which will be held in Vancouver, British Columbia, Canada on November 15-19, 2023.

Key Points: 
  • PARIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced it will present updated efficacy data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in patients with first progression/recurrence of glioblastoma (the EOGBM1-18/ROSALIE study), in an oral presentation at the Society for Neuro-Oncology (SNO) 28th Annual Meeting which will be held in Vancouver, British Columbia, Canada on November 15-19, 2023.
  • Title: EO2401 peptide immunotherapy + nivolumab +/- bevacizumab in first recurrent glioblastoma: the phase 1/2 EOGBM1-18/ROSALIE study (NCT04116658)
    Presenting Author: Prof. David Reardon, M.D., Professor of Medicine at Harvard Medical School, and Clinical Director for Dana Farber Cancer Institute
    Link to abstract published in a supplement to Neuro-Oncology, the Official Journal of the Society for Neuro-Oncology, can be found here .
  • The slides from the oral presentation will be available on Enterome’s website after the Meeting.

Smart Immune to host R&D KOL webinar on thymus-empowered ProTcell platform

Retrieved on: 
Friday, November 10, 2023
Immune system, City, Patient, Hematopoietic stem cell transplantation, Q&A, Dana–Farber Cancer Institute, Acute leukemia, Vaccine

Karine Rossignol, Co-founder and Chief Executive Officer of Smart Immune, will give an introduction to Smart Immune and its ProTcell platform.

Key Points: 
  • Karine Rossignol, Co-founder and Chief Executive Officer of Smart Immune, will give an introduction to Smart Immune and its ProTcell platform.
  • Marina Cavazzana, Co-founder and Strategic Clinical Development Advisor of Smart Immune, will present the ReSET-01 and ReSET-02 trials, including preliminary results in adult acute leukemia patients.
  • Marcel Van den Brink, President of the City of Hope Los Angles National Medical Center and Chief Physician Executive, and Smart Immune’s Scientific Advisory Board Chairman, will discuss the importance of thymic function in the immune system.
  • Olivier Negre, Chief Scientific Officer of Smart Immune, will outline preclinical data on the regenerative properties of ProTcell and its potential to unlock allogeneic T-cell medicine.